Literature DB >> 26818358

Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity.

Sungshim L Park, Maarit I Tiirikainen1, Yesha M Patel, Lynne R Wilkens1, Daniel O Stram, Loic Le Marchand1, Sharon E Murphy2.   

Abstract

Genetic variation in cytochrome P450 2A6 (CYP2A6) gene is the primary contributor to the intraindividual and interindividual differences in nicotine metabolism and has been found to influence smoking intensity. However, no study has evaluated the relationship between CYP2A6 genetic variants and the CYP2A6 activity ratio (total 3-hydroxycotinine/cotinine) and their influence on smoking intensity [total nicotine equivalents (TNE)], across five racial/ethnic groups found to have disparate rates of lung cancer. This study genotyped 10 known functional CYP2A6 genetic or copy number variants in 2115 current smokers from the multiethnic cohort study [African Americans (AA) = 350, Native Hawaiians (NH) = 288, Whites = 413, Latinos (LA) = 437 and Japanese Americans (JA) = 627] to conduct such an investigation. Here, we found that LA had the highest CYP2A6 activity followed by Whites, AA, NH and JA, who had the lowest levels. Adjusting for age, sex, race/ethnicity and body mass index, we found that CYP2A6 diplotypes were predictive of TNE levels, particularly in AA and JA (P trend < 0.0001). However, only in JA did the association remain after accounting for cigarettes per day. Also, it is only in this population that the lower activity ratio supports lower TNE levels, carcinogen exposure and thereby lower risk of lung cancer. Despite the association between nicotine metabolism (CYP2A6 activity phenotype and diplotypes) and smoking intensity (TNE), CYP2A6 levels did not correlate with the higher TNE levels found in AA nor the lower TNE levels found in LA, suggesting that other factors may influence smoking dose in these populations. Therefore, further study in these populations is recommended.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26818358      PMCID: PMC5014092          DOI: 10.1093/carcin/bgw012

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  39 in total

1.  CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

Authors:  Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

2.  CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations.

Authors:  Catherine A Wassenaar; Yuanqing Ye; Qiuyin Cai; Melinda C Aldrich; Joanne Knight; Margaret R Spitz; Xifeng Wu; William J Blot; Rachel F Tyndale
Journal:  Carcinogenesis       Date:  2014-11-21       Impact factor: 4.944

Review 3.  CYP2A6: genetics, structure, regulation, and function.

Authors:  Hannu Raunio; Minna Rahnasto-Rilla
Journal:  Drug Metabol Drug Interact       Date:  2012-05-05

4.  CYP2A6 gene deletion reduces susceptibility to lung cancer.

Authors:  M Miyamoto; Y Umetsu; H Dosaka-Akita; Y Sawamura; J Yokota; H Kunitoh; N Nemoto; K Sato; N Ariyoshi; T Kamataki
Journal:  Biochem Biophys Res Commun       Date:  1999-08-11       Impact factor: 3.575

5.  The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.

Authors:  Joseph Bloom; Anthony L Hinrichs; Jen C Wang; Linda B von Weymarn; Evan D Kharasch; Laura J Bierut; Alison Goate; Sharon E Murphy
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

6.  Is 24h nicotine equivalents a surrogate for smoke exposure based on its relationship with other biomarkers of exposure?

Authors:  Jingzhu Wang; Qiwei Liang; Paul Mendes; Mohamadi Sarkar
Journal:  Biomarkers       Date:  2011-03       Impact factor: 2.658

7.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.

Authors:  Noritaka Ariyoshi; Masami Miyamoto; Yuri Umetsu; Hideo Kunitoh; Hirotoshi Dosaka-Akita; Yu-Ichi Sawamura; Jun Yokota; Nobuo Nemoto; Kunio Sato; Tetsuya Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-09       Impact factor: 4.254

Review 8.  Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.

Authors:  Jill C Mwenifumbo; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2007-10       Impact factor: 2.533

9.  Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population.

Authors:  Natsuhiko Kumasaka; Masayuki Aoki; Yukinori Okada; Atsushi Takahashi; Kouichi Ozaki; Taisei Mushiroda; Tomomitsu Hirota; Mayumi Tamari; Toshihiro Tanaka; Yusuke Nakamura; Naoyuki Kamatani; Michiaki Kubo
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Updated information on risk factors for lung cancer: findings from the JACC Study.

Authors:  Kenji Wakai; Masahiko Ando; Kotaro Ozasa; Yoshinori Ito; Koji Suzuki; Yoshikazu Nishino; Shin-ichi Kuriyama; Nao Seki; Takaaki Kondo; Yoshiyuki Watanabe; Yoshiyuki Ohno; Akiko Tamakoshi
Journal:  J Epidemiol       Date:  2005-06       Impact factor: 3.211

View more
  27 in total

1.  CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.

Authors:  Jian-Min Yuan; Heather H Nelson; Steven G Carmella; Renwei Wang; Jacquelyn Kuriger-Laber; Aizhen Jin; Jennifer Adams-Haduch; Stephen S Hecht; Woon-Puay Koh; Sharon E Murphy
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

2.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

3.  Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk.

Authors:  Yesha M Patel; Sunghim L Park; Younghun Han; Lynne R Wilkens; Heike Bickeböller; Albert Rosenberger; Neil Caporaso; Maria Teresa Landi; Irene Brüske; Angela Risch; Yongyue Wei; David C Christiani; Paul Brennan; Richard Houlston; James McKay; John McLaughlin; Rayjean Hung; Sharon Murphy; Daniel O Stram; Christopher Amos; Loïc Le Marchand
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

Review 4.  Lung cancer health disparities.

Authors:  Bríd M Ryan
Journal:  Carcinogenesis       Date:  2018-05-28       Impact factor: 4.944

5.  Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.

Authors:  Julie-Anne Tanner; Bhagwat Prasad; Katrina G Claw; Patricia Stapleton; Amarjit Chaudhry; Erin G Schuetz; Kenneth E Thummel; Rachel F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2016-11-04       Impact factor: 4.030

6.  Racial/Ethnic Differences in Lung Cancer Incidence in the Multiethnic Cohort Study: An Update.

Authors:  Daniel O Stram; S Lani Park; Christopher A Haiman; Sharon E Murphy; Yesha Patel; Stephen S Hecht; Loic Le Marchand
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

7.  Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers.

Authors:  Dana M Carroll; Sharon E Murphy; Neal L Benowitz; Andrew A Strasser; Michael Kotlyar; Stephen S Hecht; Steve G Carmella; Francis J McClernon; Lauren R Pacek; Sarah S Dermody; Ryan G Vandrey; Eric C Donny; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-12       Impact factor: 4.254

8.  Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors.

Authors:  Gideon St Helen; Neal L Benowitz; Jasjit S Ahluwalia; Rachel F Tyndale; Newton Addo; Steven E Gregorich; Eliseo J Pérez-Stable; Lisa Sanderson Cox
Journal:  J Natl Med Assoc       Date:  2019-05-11       Impact factor: 1.798

Review 9.  Pathways to precision medicine in smoking cessation treatments.

Authors:  Li-Shiun Chen; Amy Horton; Laura Bierut
Journal:  Neurosci Lett       Date:  2016-05-18       Impact factor: 3.046

10.  Applying Tobacco, Environmental, and Dietary-Related Biomarkers to Understand Cancer Etiology and Evaluate Prevention Strategies.

Authors:  Lisa A Peterson; Silvia Balbo; Naomi Fujioka; Dorothy K Hatsukami; Stephen S Hecht; Sharon E Murphy; Irina Stepanov; Natalia Y Tretyakova; Robert J Turesky; Peter W Villalta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.